Isaac Health GUIDE model has launched – click here to book

 

The best care for every brain™

Magazine

family celebrating holidays

Navigating the Holidays with Dementia: Tips for a Stress-Free, Meaningful Celebration

The holidays are a time for togetherness and joy. But for individuals living with dementia and their families, it can also come with unique challenges. Managing the expectations of family gatherings, maintaining routines, and navigating emotional or behavioral changes require thoughtful planning. Here are strategies curated by the Isaac Health team on how to make …

Navigating the Holidays with Dementia: Tips for a Stress-Free, Meaningful Celebration Read More »

Isaac Health Joins Alzheimer’s Association Dementia Care Navigation Roundtable

Isaac Health is honored to join the Alzheimer’s Association Dementia Care Navigation Roundtable (AADCNR), an initiative dedicated to improving the lives of individuals living with Alzheimer’s and related dementias (ADRD) through coordinated care models. The Roundtable convenes health systems, payers, clinicians, and researchers to establish consistent, equitable processes for dementia care navigation, ensuring comprehensive support …

Isaac Health Joins Alzheimer’s Association Dementia Care Navigation Roundtable Read More »

Isaac Health Awarded National Telehealth Accreditation from The Joint Commission

New York, NY, December 4, 2024 – Isaac Health has earned The Joint Commission’s Gold Seal of Approval® for Telehealth Accreditation by demonstrating continuous compliance with its performance standards. The Gold Seal is a symbol of quality that reflects a health care organization’s commitment to providing safe and quality patient care at the highest standards.  …

Isaac Health Awarded National Telehealth Accreditation from The Joint Commission Read More »

Bringing Specialized Dementia Care to Montana’s Families

For families in Montana affected by Alzheimer’s Disease and Related Dementias (ADRD), finding specialized care can be challenging — especially in rural areas. Montana is classified as a “dementia neurology desert,” meaning it is projected to have fewer than 10 neurologists available for every 10,000 people with dementia in 2025. Today, approximately 21,000 Montanans over …

Bringing Specialized Dementia Care to Montana’s Families Read More »

Kisunla

FDA Approval of Donanemab Marks Major Advance in Alzheimer’s Treatment

July 2, 2024 – The U.S. Food and Drug Administration (FDA) has approved donanemab, a groundbreaking treatment for Alzheimer’s disease. Branded as Kisunla™ (pronounced kih-SUHN-lah) by Eli Lilly, donanemab is an amyloid plaque-targeting therapy for persons living with mild cognitive impairment (MCI) or in the mild dementia stage of Alzheimer’s disease with confirmed amyloid pathology. …

FDA Approval of Donanemab Marks Major Advance in Alzheimer’s Treatment Read More »

Isaac Health Joins CMS GUIDE Model Program to Enhance Dementia Care Nationwide

NEW YORK, New York, July 1, 2024 – Isaac Health, a leading national telehealth provider of brain health and dementia care, is a participant in the Centers for Medicare & Medicaid Services’ (CMS) Guiding an Improved Dementia Experience (GUIDE) Model, launching today. This program enables Isaac Health to deliver comprehensive, personalized care to individuals living …

Isaac Health Joins CMS GUIDE Model Program to Enhance Dementia Care Nationwide Read More »

CMS Innovation

CMS Launches New Dementia Care Management Program

The Centers for Medicare & Medicaid Services (CMS) has launched a new dementia care management program called GUIDE (Guiding an Improved Dementia Experience). This program is designed to improve the quality of care and support for people living with dementia and their caregivers. Isaac Health is a proud participant in the GUIDE Model right from …

CMS Launches New Dementia Care Management Program Read More »

Utilization management

White Paper on cost implications of Leqembi and other anti-amyloid drugs for payers and ACOs and options for utilization management

Introduction: The recent full approval of Lecanemab (Leqembi) by the FDA has ushered in a new era in the treatment of Alzheimer’s disease. As the first disease-modifying treatment to receive such approval, Leqembi offers hope to patients with early-stage Alzheimer’s. However, its adoption poses cost implications for payers and risk-bearing health systems. In a newly …

White Paper on cost implications of Leqembi and other anti-amyloid drugs for payers and ACOs and options for utilization management Read More »

Neurologist with brain scan

Leqembi – Implications for Health Insurance Payers: A Comprehensive Analysis

Introduction: On July 6, 2023, the FDA granted full approval to Lecanemab (Leqembi), marking a significant milestone as the first disease-modifying treatment for Alzheimer’s disease to receive such approval. This white paper aims to inform health insurance employees about the implications of Leqembi’s approval and offer insights into coverage considerations and potential cost implications. Coverage …

Leqembi – Implications for Health Insurance Payers: A Comprehensive Analysis Read More »

Join our community

* indicates required

Request patient flyers